Клиническая задача и разбор №13. Пациентка с сахарным диабетом 2-го типа и факторами сердечно-сосудистого риска
- Количество записей: 43
-
- По дате
- По просмотрам
-
Спонсорские материалы
Инструкция по медицинскому применению лекарственного препарата Форсига
Гипогликемическое средство для перорального применения – ингибитор натрийзависимого переносчика глюкозы 2 типа
Подробнее
891
-
Спонсорские материалы
Листовка по препарату Форсига
Единственный ПССП, доказавший снижение риска ХСН у пациентов с двумя и более факторами СС риска
Подробнее
682
-
Зарубежные материалы
Prevalence of Low Glomerular Filtration Rate in Nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III)
End-stage renal disease is an important and costly health problem. Strategies for its prevention are urgently needed. Knowledge of the population-based prevalence of renal insufficiency in nondiabetic adults would inform such strategies.
Подробнее
557
-
Зарубежные материалы
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes.
Подробнее
705
-
Зарубежные материалы
Eligibility Varies Among the 4 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Outcomes Trials: Implications for the General Type 2 Diabetes US Population
In 2015, more than 23 million adults in the United States had a diagnosis of diabetes, with an estimated 95% of cases being type 2 diabetes (T2D). Patients with T2D are at increased risk of cardiovascular disease (CVD),2 and therefore, improvement of cardiovascular (CV) outcomes is a goal of diabetes management.3,4 Good glycemic control in T2D has been associated with a reduced risk of microvascul ...
Подробнее
631
-
Зарубежные материалы
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium – glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.
Подробнее
567
-
Зарубежные материалы
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
The impact of insulin secretagogues (ISs) on long-term major clinical outcomes in type 2 diabetes remains unclear. We examined mortality and cardiovascular risk associated with all available ISs compared with metformin in a nationwide study.
Подробнее
815
-
Зарубежные материалы
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
Chronic kidney disease is a worldwide public health problem with an increasing incidence and prevalence, poor outcomes, and high cost. Outcomes of chronic kidney disease include not only kidney failure but also complications of decreased kidney function and cardiovascular disease.
Подробнее
665
-
Зарубежные материалы
Diabetes with early kidney involvement may shorten life expectancy by 16 years
This study aimed to identify the excess risks associated with diabetic patients with early kidney involvement (early diabetic kidney disease). The mortality risks of early diabetic kidney disease, defined as diabetes in early stages 1-3 chronic kidney disease (CKD), were assessed from a cohort of 512,700 adults in Taiwan participating in a health surveillance program from 1994-2008. Three related ...
Подробнее
1054
-
Зарубежные материалы
Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?
Diabetes mellitus is a chronic condition that occurs when the body cannot produce enough or effectively use of insulin. Compared with individuals without diabetes, patients with type 2 diabetes mellitus have a considerably higher risk of cardiovascular morbidity and mortality, and are disproportionately affected by cardiovascular disease.
Подробнее
771
-
Зарубежные материалы
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined.
Подробнее
609
-
Зарубежные материалы
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 ...
Подробнее
857
-
Зарубежные материалы
2018 ESC/ESH Guidelines for the management of arterial hypertension
The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)
Подробнее
683
-
Зарубежные материалы
Cardiorenal Syndrome
The term cardiorenal syndrome (CRS) increasingly has been used without a consistent or well-accepted definition. To include the vast array of interrelated derangements, and to stress the bidirectional nature of heartkidney interactions, we present a new classification of the CRS with 5 subtypes that reflect the pathophysiology, the time-frame, and the nature of concomitant cardiac and renal dysfun ...
Подробнее
709
-
Зарубежные материалы
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.
Подробнее
732
- ← Предыдущая
- 1 (current)
- 2
- 3
- Следующая →